November 26, 2024
Collaboration achieves significant health gains for high-risk participants in type 2 diabetes program
October 16, 2024
Indigenous communities and partners unite to bridge gaps in healthcare through PATHWAYS initiative
October 11, 2024
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
September 16, 2024
University of Saskatchewan’s Dr. Diego Moya named 2024 Metacam® Bovine Welfare Award winner
September 16, 2024
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study
July 23, 2024
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 18, 2024
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
June 07, 2024
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
May 07, 2024
Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Media contacts
Communications, Media & Public Relations
Director, Communications
Phone (905) 631-4713
Mobile (905) 599-2364
Communications, Media & Public Relations
Corporate Communications
Phone (905) 631-4531
Mobile (647) 637-8265
